ProPhase Labs (NASDAQ:PRPH) & Enliven Therapeutics (NASDAQ:ELVN) Head-To-Head Comparison

ProPhase Labs (NASDAQ:PRPH) and Enliven Therapeutics (NASDAQ:ELVN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.

Volatility & Risk

ProPhase Labs has a beta of -0.54, indicating that its share price is 154% less volatile than the S&P 500. Comparatively, Enliven Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500.

Profitability

This table compares ProPhase Labs and Enliven Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProPhase Labs	-825.01%	-482.05%	-88.90%
Enliven Therapeutics	N/A	-24.88%	-23.96%

Insider & Institutional Ownership

9.4% of ProPhase Labs shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by insiders. Comparatively, 25.9% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations and price targets for ProPhase Labs and Enliven Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProPhase Labs	1	0	0	0	1.00
Enliven Therapeutics	1	0	4	0	2.60

Enliven Therapeutics has a consensus target price of $41.00, suggesting a potential upside of 38.09%. Given Enliven Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Enliven Therapeutics is more favorable than ProPhase Labs.

Earnings & Valuation

This table compares ProPhase Labs and Enliven Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProPhase Labs	$5.06 million	0.18	-$53.36 million	($3.90)	-0.04
Enliven Therapeutics	N/A	N/A	-$89.02 million	($1.84)	-16.14

ProPhase Labs has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.

Summary

Enliven Therapeutics beats ProPhase Labs on 10 of the 13 factors compared between the two stocks.

About ProPhase Labs

ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.